Communiqués Cardiol Therapeutics Inc.

Actions

CRDL

CA14161Y2006

Recherche biotechnologique et médicale

Temps Différé Toronto S.E. 15:45:10 18/08/2026			Varia. 5j.	Varia. 1 janv.
2,440 ^CAD	-2,01 %		+15,64 %	+86,26 %

12/08	Cardiol Therapeutics Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
11/05	Cardiol Therapeutics Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

05/08	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	PR
05/08	Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference	AQ
14/07	Cardiol Therapeutics : rsquo; Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PU
14/07	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	PR
14/07	Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association	AQ
09/07	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	PR
09/07	Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit	AQ
25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	PR
25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	AQ
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	PR
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	AQ
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	PR
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	AQ
07/05	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	PR
07/05	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	AQ
28/04	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	PR
28/04	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	AQ
14/04	Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart	NE
01/04	Cardiol Therapeutics Announces Year-End 2025 Update on Operations	NE
25/02	Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference	NE
10/02	Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure	NE
23/01	Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million	NE
16/01	Canadian Investment Regulatory Organization Trade Resumption - CRDL	AQ
16/01	Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million	NE
16/01	Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million	NE